The Use of Intranasal Fentanyl for the Palliation of Incident Dyspnea in Advanced Congestive Heart Failure: A Pilot Study

Journal of Palliative Care
Jana PilkeyJonathan Wong

Abstract

Dyspnea is distressing in palliative patients with end-stage heart failure and many are hospitalized to optimize this symptom. We hoped to conduct a pilot study to determine whether the administration of intranasal fentanyl would decrease activity-induced dyspnea in this patient population. Patients performed two 6-minute walk tests with and without the administration of 50 μg of intranasal fentanyl. Vital signs were recorded before and after each walk, as were participant reported dyspnea and adverse events scores. Twenty-four patients were screened, 13 were deemed eligible, and 6 completed the study. Dyspnea scores changed from a mean of 6.00 immediately after the walk without fentanyl to a mean of 3.83 after the walk with fentanyl ( P = .048). Mean respiratory rate decreased from 21.0 to 18.7 ( P = .034) breaths per minute and was considered a favorable outcome by the participants. Distance walked did not significantly increase with the fentanyl pretreatment (136.0-144.2 m; P = .283), although the participants reported feeling better while walking a similar distance. In this pilot study, the preadministration of intranasal fentanyl prior to activity in palliative, end-stage hospitalized heart failure patients, safely reduced...Continue Reading

References

Jul 1, 1996·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·P Peeters, T Mets
Jan 1, 1997·Journal of the American College of Cardiology·T P ChuaA J Coats
Dec 13, 2000·Statistics in Medicine·G D PinnaM Sanarico
Jul 2, 2002·American Journal of Respiratory and Critical Care Medicine·UNKNOWN ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories
Jul 26, 2002·Acta Anaesthesiologica Scandinavica·O DaleE D Kharasch
Nov 28, 2002·European Journal of Heart Failure·M J JohnsonH J Dargie
Jul 10, 2003·American Heart Journal·Grace WuVera Bittner
Sep 20, 2008·Palliative Medicine·D J A JanssenJ M G A Schols
Oct 29, 2008·Journal of Pain and Symptom Management·Thomas Sitte, Claudia Bausewein
Sep 2, 2009·Journal of Palliative Medicine·Thomas J SmithPatricia Corrigan
Jan 9, 2010·American Journal of Respiratory and Critical Care Medicine·Richard A MularskiSydney Dy
Jun 30, 2011·European Journal of Heart Failure·Stephen G OxberryMiriam J Johnson
Jun 5, 2012·Journal of Palliative Medicine·Nicole M L Veldhorst-JanssenPaul-Hugo M van der Kuy
Feb 2, 2013·Journal of Palliative Medicine·Stephen G OxberryMiriam J Johnson
May 20, 2014·Annals of Physical and Rehabilitation Medicine·L IngleA L Clark
Oct 30, 2014·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Sebastiano MercadanteAlessandra Casuccio
Feb 1, 2013·Drug Delivery and Translational Research·Peter WattsMichael Perelman
Sep 19, 2015·Cancer·Miriam J Johnson, David C Currow
Oct 13, 2015·Journal of Pain & Palliative Care Pharmacotherapy·Dulce RogríguezMaite Murillo
Apr 20, 2017·Current Heart Failure Reports·Huiyun DuRobyn A Clark
Apr 27, 2017·Orphanet Journal of Rare Diseases·Rudolf SchroverKaustuv Bhattacharya
Nov 8, 2017·The Canadian Journal of Cardiology·Justin A EzekowitzBruce Sussex

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.